US Patent 8,669,279: Bendamustine Hydrochloride Form 3 Claims, Scope, Expiration and Patent Landscape

US Patent 8,669,279 protects a specific crystalline polymorph of bendamustine hydrochloride, identified as Form 3 by defined X-ray powder diffraction peaks. Its strongest protection is directed to the polymorphic active pharmaceutical ingredient, while dependent claims extend coverage to pharmaceutical compositions, lyophilized products, excipient combinations, organic-solvent systems and specified treatment methods. The patent was issued on March 11, 2014, and has an estimated US patent-term endpoint in approximately 2029, subject to the recorded patent-term adjustment and terminal-disclaimer status.[1]

What does US Patent 8,669,279 protect?

US 8,669,279 protects bendamustine hydrochloride Form 3 and products containing that form. The independent claim categories are:

Claim category	Claims	Protected subject matter
Crystalline API	1	Bendamustine hydrochloride Form 3 identified by XRPD peaks at approximately 7.9°, 15.5° and 26.1° 2θ
Additional XRPD identification	2	Form 3 with one or more additional reflections at approximately 10.6°, 19.7° and 23.3° 2θ
Polymorphic purity	3	Form 3 substantially free of other crystalline bendamustine hydrochloride forms
Compositions	4-12	Compositions containing Form 3, with or without excipients or amorphous bendamustine
Lyophilized products	13-20	Lyophilized compositions containing Form 3, excipients and an organic solvent
Therapeutic methods	21-22	Treatment of specified cancers using a composition containing Form 3

The patent is therefore broader than a pure polymorph claim in product-development terms, but the claims remain dependent on the presence of Form 3. A product containing bendamustine hydrochloride in another crystalline form, or only in amorphous form, does not fall within the literal scope of claim 1.

How is bendamustine hydrochloride Form 3 defined?

Form 3 is defined primarily by XRPD diffraction characteristics rather than by a chemical change in the bendamustine molecule. The claimed material has the same molecular formula and active moiety as other bendamustine hydrochloride forms but differs in crystal packing, solid-state structure and diffraction pattern.

Claim 1 requires reflections at approximately:

Required reflection	Position, degrees 2θ
First peak	7.9
Second peak	15.5
Third peak	26.1 ± 0.2

Claim 2 adds optional identifying reflections at approximately 10.6°, 19.7° and 23.3° 2θ. Because claim 2 requires only one or more of those additional peaks, it is narrower than claim 1 but does not require all three.

Why the XRPD limitation matters

XRPD limitations can create an infringement issue that is highly dependent on analytical testing. The relevant question is whether the accused bendamustine hydrochloride material exhibits the claimed Form 3 diffraction pattern under materially comparable test conditions.

The analysis may involve:

peak position;
peak intensity;
relative intensity;
instrument calibration;
sample preparation;
crystallinity;
solvent and hydration state;
mixtures of polymorphs; and
amorphous content.

A batch containing a mixture of Form 3 and another crystalline form may still satisfy claim 1 if the required Form 3 reflections are present. Claims 3, 6, 7 and 15 impose a separate purity limitation by requiring that the material or composition be “substantially free” of other crystalline forms.

How strong are the composition and lyophilized-product claims?

Claims 4-20 extend the patent from the API to dosage-form and manufacturing formats.

Composition claims

Claims 4 and 12 cover a composition containing Form 3 and a pharmaceutical composition containing Form 3. Claims 5 and 10-11 identify excipients, including mannitol, phosphate salts, organic acids, sugars, gelatin, glycine, glycerin, dextran, trehalose and hetastarch.

The most commercially relevant excipient limitation is mannitol:

claim 11 covers compositions containing Form 3 and mannitol;
claim 17 covers lyophilized compositions containing Form 3 and mannitol;
claim 20 narrows the product to Form 3, amorphous bendamustine and mannitol.

The composition claims do not require a particular bendamustine concentration, dosage strength, vial size, reconstitution volume or administration route unless those limitations appear elsewhere in the patent specification or regulatory product documentation.

Amorphous bendamustine combinations

Claims 8, 9, 14 and 20 expressly permit compositions containing both crystalline Form 3 and amorphous bendamustine hydrochloride. This is important because a formulation containing amorphous material is not automatically outside the patent. The presence of amorphous bendamustine does not avoid infringement where Form 3 is also present and the remaining claim limitations are met.

Lyophilized compositions

Claim 13 requires:

crystalline Form 3;
at least one pharmaceutically acceptable excipient; and
an organic solvent.

Claim 18 identifies methanol, ethanol, n-propanol, isopropanol, n-butanol and tert-butanol. Claim 19 narrows the solvent to tert-butanol. Claim 20 adds amorphous bendamustine and mannitol.

These claims are directed to a product configuration and may also create process-development risk. A manufacturer may avoid a particular claim by using a non-listed solvent, a different solid-state form, or a formulation that does not contain the claimed combination. Those alternatives would require separate noninfringement and validity analysis.

What do the treatment-method claims cover?

Claims 21 and 22 cover administration of a composition containing Form 3 to treat:

chronic lymphocytic leukemia;
Hodgkin’s disease;
non-Hodgkin’s lymphoma;
multiple myeloma; or
breast cancer.

Claim 22 narrows non-Hodgkin’s lymphoma to indolent B-cell non-Hodgkin’s lymphoma.

The method claims are not limited on their face to a specific dose, dosing schedule, infusion duration, treatment line or patient biomarker. They require administration of a composition containing the claimed crystalline form. A method claim may be relevant to a marketed product even where the product patent is difficult to enforce against the manufacturer because treatment is performed by physicians or healthcare providers.

The FDA-approved bendamustine products have historically been indicated for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma, among other label-specific distinctions. The broader cancer list in claim 21 should not be treated as evidence of current FDA approval.[2][3]

When does US Patent 8,669,279 lose exclusivity?

US Patent 8,669,279 issued on March 11, 2014. Its expected expiration is approximately in 2029 based on the underlying US/PCT filing timeline. The precise endpoint must be determined from the USPTO patent record, including any patent-term adjustment and terminal disclaimer.[1]

Milestone	Date or status
Patent	US 8,669,279
Subject	Crystalline forms of bendamustine hydrochloride
Patent holder at issuance	Cephalon, Inc.
Issue date	March 11, 2014
Estimated ordinary expiration	Approximately 2029
Patent-term adjustment	Must be taken from USPTO record
Regulatory exclusivity	Separate from patent term
Relevant FDA pathway	NDA for branded bendamustine products; ANDA for generics

Patent expiry does not necessarily equal commercial launch permission. A generic applicant may launch before expiry if it obtains a favorable court judgment, reaches a settlement permitting entry, or successfully challenges listed patents. Conversely, a patent may expire without immediate generic entry because of manufacturing, supply, formulation or regulatory barriers.

What is the Orange Book status of US 8,669,279?

The Orange Book lists patents identified by an NDA holder as claiming the approved drug, formulation or method of use. A crystalline API patent is not automatically listed merely because it covers the active ingredient used in an approved product. Listing depends on the patent’s relationship to the approved NDA product and FDA Orange Book rules.[4]

Bendamustine products have included:

Product	Sponsor or commercial party	Regulatory form
Treanda	Cephalon, later Teva-related commercial ownership	NDA
Bendeka	Eagle Pharmaceuticals	NDA
Generic bendamustine hydrochloride injection	Multiple ANDA applicants	ANDA

The commercial importance of US 8,669,279 depends on whether it is listed against the relevant NDA and on the specific dosage form covered by the listing. Orange Book-listed formulation patents associated with bendamustine injection products may present a more direct barrier to ANDA approval than a polymorph patent that is not listed or that does not read on the approved formulation.

What Paragraph IV challenges affect bendamustine products?

An ANDA applicant filing a Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable or will not be infringed by the proposed generic product. The NDA holder can trigger a 30-month stay by filing suit within the statutory period under the Hatch-Waxman framework.[5]

For US 8,669,279, the relevant questions are:

Was the patent listed against the applicable bendamustine NDA?
Did an ANDA applicant certify Paragraph IV against it?
Did the NDA holder sue within 45 days?
Was a 30-month stay imposed?
Did the case end in settlement, judgment or dismissal?
Was generic entry permitted before the patent’s estimated expiration?

A Paragraph IV challenge would likely focus on both infringement and validity. Infringement analysis would require XRPD testing of the proposed generic API and finished product. Validity issues could include anticipation, obviousness, enablement, written description and indefiniteness, depending on the patent specification and prior-art record.

No conclusion about a specific Paragraph IV outcome follows from the issued claims alone. The patent’s litigation status must be distinguished from the broader litigation history involving bendamustine liquid formulations and other product patents.

What validity risks affect the Form 3 claims?

Anticipation

An anticipation challenge would require a single prior-art reference disclosing bendamustine hydrochloride Form 3 and the claimed XRPD pattern, including the relevant reflections and tolerances. General disclosure of bendamustine hydrochloride or a different polymorph would not necessarily anticipate claim 1.

Obviousness

The principal obviousness theory would likely combine:

known bendamustine hydrochloride;
routine polymorph screening;
known solid-state characterization methods;
predictable crystallization solvents; and
a reasonable expectation of identifying a crystalline form.

The patent holder would respond that Form 3 has unexpected properties, improved stability, reproducibility, processing advantages or pharmaceutical performance. The strength of that defense depends on comparative data in the specification and the closest prior art.

Claim construction

Potential claim-construction disputes include:

the meaning of “Form 3”;
whether all three claim 1 reflections must fall within ±0.2°;
the significance of peak intensity;
the meaning of “substantially free”;
whether amorphous bendamustine is permitted under claims 3, 6, 7 and 15;
whether a product containing trace Form 3 infringes;
whether the composition must be manufactured by a particular process; and
whether “comprising” permits additional polymorphs or excipients.

“Comprising” generally permits additional elements. That makes the composition claims potentially relevant to products containing Form 3 along with other ingredients or solid-state fractions, subject to the express “substantially free” limitations in narrower claims.

How does this patent compare with bendamustine formulation patents?

US 8,669,279 is a solid-state patent. It should be evaluated separately from formulation patents covering aqueous stability, ready-to-use solutions, lyophilized formulations or reconstitution systems.

Patent type	Main barrier	Typical design-around
Form 3 polymorph patent	Presence and identity of crystalline Form 3	Use a different polymorph or amorphous material
Liquid formulation patent	Specified solvent, pH, concentration or stabilizer	Change formulation parameters
Lyophilized formulation patent	Form 3 plus excipient and organic-solvent system	Use a different solvent, excipient or solid form
Method-of-use patent	Administration for a specified cancer or patient population	Use a different indication or dosing method
Manufacturing patent	Process conditions or crystallization sequence	Modify process while producing a non-infringing form

A generic applicant must clear the full patent estate, not only US 8,669,279. A design-around that avoids Form 3 may still infringe an independent formulation or manufacturing patent.

What manufacturing and IP barriers does Form 3 create?

Form 3 may affect:

crystallization solvent selection;
drying temperature;
residual-solvent control;
seed selection;
milling;
particle-size distribution;
polymorph conversion during storage;
hydration and desolvation;
lyophilization cycle design; and
batch-release testing.

A manufacturer can face infringement risk even if Form 3 is not intentionally used. Polymorph conversion can occur during isolation, drying, storage or reconstitution. Finished-product testing should therefore examine both the API and the lyophilized or reconstituted product.

The patent claims do not require a particular particle size or purity percentage. That gives the patent holder a potentially useful infringement position against products that contain Form 3 but differ in physical processing details.

Are biosimilars relevant to bendamustine?

No. Bendamustine hydrochloride is a small-molecule drug. Competitors generally use the ANDA pathway rather than the 351(k) biosimilar pathway. The relevant competitive risks are generic bendamustine injections, authorized generic strategies, formulation-specific products and alternative oncology therapies.[4][6]

What companies are exposed to this patent?

The principal commercial parties are:

Teva and predecessor Cephalon interests associated with Treanda;
Eagle Pharmaceuticals, associated with Bendeka;
generic bendamustine hydrochloride manufacturers;
contract manufacturers producing bendamustine API;
injectable oncology suppliers; and
distributors and purchasers relying on a particular formulation or API source.

Revenue exposure is greatest for products that require crystalline Form 3, particularly lyophilized bendamustine products using mannitol and tert-butanol-related manufacturing processes. Revenue exposure is lower where a product uses a demonstrably different polymorph or amorphous API and is supported by independent solid-state characterization.

Key Takeaways

US 8,669,279 is directed to bendamustine hydrochloride Form 3, identified by XRPD reflections at approximately 7.9°, 15.5° and 26.1° 2θ.
Claims 4-20 extend coverage to compositions, mannitol-containing products, lyophilized products and organic-solvent systems.
Claims 8, 9, 14 and 20 permit certain compositions containing both Form 3 and amorphous bendamustine.
Claim 21 covers treatment of several cancers, while claim 22 narrows non-Hodgkin’s lymphoma to indolent B-cell disease.
The estimated patent-term endpoint is approximately 2029, subject to USPTO term adjustment and any terminal disclaimer.
The key infringement issue is analytical: whether the accused API or product contains Form 3 with the claimed XRPD pattern.
A different bendamustine polymorph or amorphous API may avoid the literal Form 3 claims but does not necessarily avoid other bendamustine formulation or manufacturing patents.
Bendamustine is a small molecule, so generic competition proceeds through ANDA Paragraph IV mechanisms rather than biosimilar litigation.
FDA approval, Orange Book listing and patent expiration are separate issues and must be assessed independently.

FAQs About US Patent 8,669,279

Does US 8,669,279 cover all bendamustine hydrochloride?

No. It covers a specific crystalline form, Form 3, identified by XRPD characteristics. It does not expressly cover every crystalline or amorphous form of bendamustine hydrochloride.

Can a generic avoid the patent by using amorphous bendamustine?

Potentially, but only if the generic product is free of the claimed Form 3 or otherwise does not satisfy the applicable composition claims. Claims 8, 9, 14 and 20 expressly cover some compositions containing both Form 3 and amorphous bendamustine.

Does the patent cover Bendeka?

Coverage depends on the actual solid-state form in the approved product, the product’s manufacturing process and any Orange Book listing. The patent text alone does not establish product-specific infringement.

Is a lyophilized bendamustine product automatically covered?

No. The lyophilized product must contain Form 3 and satisfy the excipient and organic-solvent limitations of the applicable claim. Claim 19 specifically requires tert-butanol, and claim 20 adds amorphous bendamustine and mannitol.

What laboratory test is most important in a Form 3 infringement analysis?

XRPD is the central test because the independent product claim identifies Form 3 through specified diffraction reflections. Differential scanning calorimetry, thermogravimetric analysis, microscopy and solid-state NMR may support the analysis but do not replace the claimed XRPD limitations.

References

United States Patent and Trademark Office. (2014). US Patent No. 8,669,279, Crystalline forms of bendamustine hydrochloride.
U.S. Food and Drug Administration. (2023). Treanda (bendamustine hydrochloride) prescribing information.
U.S. Food and Drug Administration. (2023). Bendeka (bendamustine hydrochloride) prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
21 U.S.C. § 355(j); 35 U.S.C. § 271(e).
U.S. Food and Drug Administration. (2024). Abbreviated new drug application process.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-002	May 1, 2009	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
Cephalon	TREANDA	bendamustine hydrochloride	POWDER;INTRAVENOUS	022249-001	Mar 20, 2008	AP	RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial			Y		⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	072777	⤷ Start Trial
Canada	2718939	⤷ Start Trial
Chile	2009000742	⤷ Start Trial
China	101980698	⤷ Start Trial
China	103550159	⤷ Start Trial
China	105693620	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,669,279

Which drugs does patent 8,669,279 protect, and when does it expire?

Summary for Patent: 8,669,279